219 related articles for article (PubMed ID: 21857985)
1. Chronic myeloid leukemia patients in prolonged remission following interferon-α monotherapy have distinct cytokine and oligoclonal lymphocyte profile.
Kreutzman A; Rohon P; Faber E; Indrak K; Juvonen V; Kairisto V; Voglová J; Sinisalo M; Flochová E; Vakkila J; Arstila P; Porkka K; Mustjoki S
PLoS One; 2011; 6(8):e23022. PubMed ID: 21857985
[TBL] [Abstract][Full Text] [Related]
2. Enlarged memory T-cell pool and enhanced Th1-type responses in chronic myeloid leukemia patients who have successfully discontinued IFN-α monotherapy.
Ilander M; Kreutzman A; Rohon P; Melo T; Faber E; Porkka K; Vakkila J; Mustjoki S
PLoS One; 2014; 9(1):e87794. PubMed ID: 24498197
[TBL] [Abstract][Full Text] [Related]
3. Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy.
Kreutzman A; Juvonen V; Kairisto V; Ekblom M; Stenke L; Seggewiss R; Porkka K; Mustjoki S
Blood; 2010 Aug; 116(5):772-82. PubMed ID: 20413659
[TBL] [Abstract][Full Text] [Related]
4. Immunological effects of interferon-alpha on chronic myelogenous leukemia.
de Castro FA; Palma PV; Morais FR; Simões BP; Carvalho PV; Ismael SJ; Lima CP; Voltarelli JC
Leuk Lymphoma; 2003 Dec; 44(12):2061-7. PubMed ID: 14959848
[TBL] [Abstract][Full Text] [Related]
5. Imatinib and pegylated IFN-α2b discontinuation in first-line chronic myeloid leukemia patients following a major molecular response.
Koskenvesa P; Kreutzman A; Rohon P; Pihlman M; Vakkila E; Räsänen A; Vapaatalo M; Remes K; Lundán T; Hjorth-Hansen H; Vakkila J; Simonsson B; Mustjoki S; Porkka K
Eur J Haematol; 2014; 92(5):413-20. PubMed ID: 24372965
[TBL] [Abstract][Full Text] [Related]
6. Profiles of NK cell subsets are associated with successful tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia and changes following interferon treatment.
Kong J; Qin YZ; Zhao XS; Hou Y; Liu KY; Huang XJ; Jiang H
Ann Hematol; 2021 Oct; 100(10):2557-2566. PubMed ID: 34278524
[TBL] [Abstract][Full Text] [Related]
7. Flow cytometry and targeted immune transcriptomics identify distinct profiles in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors with or without interferon-α.
Alves R; McArdle SEB; Vadakekolathu J; Gonçalves AC; Freitas-Tavares P; Pereira A; Almeida AM; Sarmento-Ribeiro AB; Rutella S
J Transl Med; 2020 Jan; 18(1):2. PubMed ID: 31900171
[TBL] [Abstract][Full Text] [Related]
8. Phenotypic and functional characterization of the host immune compartment of chronic myeloid leukaemia patients in complete haematological remission.
Guarini A; Breccia M; Montefusco E; Petti MC; Zepparoni A; Vitale A; Foa R
Br J Haematol; 2001 Apr; 113(1):136-42. PubMed ID: 11328293
[TBL] [Abstract][Full Text] [Related]
9. Restoration of Th1 cytokine synthesis by T cells of patients with chronic myelogenous leukemia in cytogenetic and hematologic remission with interferon-alpha.
Reuben JM; Lee BN; Johnson H; Fritsche H; Kantarjian HM; Talpaz M
Clin Cancer Res; 2000 May; 6(5):1671-7. PubMed ID: 10815885
[TBL] [Abstract][Full Text] [Related]
10. Expression of interferon regulatory factor 4 in chronic myeloid leukemia: correlation with response to interferon alfa therapy.
Schmidt M; Hochhaus A; König-Merediz SA; Brendel C; Proba J; Hoppe GJ; Wittig B; Ehninger G; Hehlmann R; Neubauer A
J Clin Oncol; 2000 Oct; 18(19):3331-8. PubMed ID: 11013272
[TBL] [Abstract][Full Text] [Related]
11. Intracellular cytokine analysis of interferon-gamma in T cells of patients with chronic myeloid leukemia.
Aswald JM; Lipton JH; Messner HA
Cytokines Cell Mol Ther; 2002 Dec; 7(2):75-82. PubMed ID: 12607798
[TBL] [Abstract][Full Text] [Related]
12. Decrease in CD3-negative-CD8dim(+) and Vdelta2/Vgamma9 TcR+ peripheral blood lymphocyte counts, low perforin expression and the impairment of natural killer cell activity is associated with chronic hepatitis C virus infection.
Pár G; Rukavina D; Podack ER; Horányi M; Szekeres-Barthó J; Hegedüs G; Paál M; Szereday L; Mózsik G; Pár A
J Hepatol; 2002 Oct; 37(4):514-22. PubMed ID: 12217606
[TBL] [Abstract][Full Text] [Related]
13. IFN-α with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia.
Huuhtanen J; Ilander M; Yadav B; Dufva OM; Lähteenmäki H; Kasanen T; Klievink J; Olsson-Strömberg U; Stentoft J; Richter J; Koskenvesa P; Höglund M; Söderlund S; Dreimane A; Porkka K; Gedde-Dahl T; Gjertsen BT; Stenke L; Myhr-Eriksson K; Markevärn B; Lübking A; Dimitrijevic A; Udby L; Bjerrum OW; Hjorth-Hansen H; Mustjoki S
J Clin Invest; 2022 Sep; 132(17):. PubMed ID: 36047494
[TBL] [Abstract][Full Text] [Related]
14. Increased IFN-gamma synthesis by T cells from patients on imatinib therapy for chronic myeloid leukemia.
Aswald JM; Lipton JH; Aswald S; Messner HA
Cytokines Cell Mol Ther; 2002; 7(4):143-9. PubMed ID: 14660054
[TBL] [Abstract][Full Text] [Related]
15. Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia.
Burchert A; Müller MC; Kostrewa P; Erben P; Bostel T; Liebler S; Hehlmann R; Neubauer A; Hochhaus A
J Clin Oncol; 2010 Mar; 28(8):1429-35. PubMed ID: 20142590
[TBL] [Abstract][Full Text] [Related]
16. Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy.
Rohon P; Porkka K; Mustjoki S
Eur J Haematol; 2010 Nov; 85(5):387-98. PubMed ID: 20662899
[TBL] [Abstract][Full Text] [Related]
17. Interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia.
Burchert A; Wölfl S; Schmidt M; Brendel C; Denecke B; Cai D; Odyvanova L; Lahaye T; Müller MC; Berg T; Gschaidmeier H; Wittig B; Hehlmann R; Hochhaus A; Neubauer A
Blood; 2003 Jan; 101(1):259-64. PubMed ID: 12393722
[TBL] [Abstract][Full Text] [Related]
18. Expansions of tumor-reactive Vdelta1 gamma-delta T cells in newly diagnosed patients with chronic myeloid leukemia.
Knight A; Piskacek M; Jurajda M; Prochazkova J; Racil Z; Zackova D; Mayer J
Cancer Immunol Immunother; 2023 May; 72(5):1209-1224. PubMed ID: 36376516
[TBL] [Abstract][Full Text] [Related]
19. PR1-specific T cells are associated with unmaintained cytogenetic remission of chronic myelogenous leukemia after interferon withdrawal.
Kanodia S; Wieder E; Lu S; Talpaz M; Alatrash G; Clise-Dwyer K; Molldrem JJ
PLoS One; 2010 Jul; 5(7):e11770. PubMed ID: 20668669
[TBL] [Abstract][Full Text] [Related]
20. Activated naïve γδ T cells accelerate deep molecular response to BCR-ABL inhibitors in patients with chronic myeloid leukemia.
Chang YC; Chiang YH; Hsu K; Chuang CK; Kao CW; Chang YF; Chang MC; Lim KH; Cheng HI; Hsu YN; Chen CG
Blood Cancer J; 2021 Nov; 11(11):182. PubMed ID: 34785653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
